- Immunohistochemistry in 32 patients with primary diffuse large B-cell lymphoma of the breast.
| Immunohistochemistry | All | 5 years progression-free survival | 5 years overall survival | ||
|---|---|---|---|---|---|
| Precentages | P-values | Precentages | P-values | ||
| Ki-67 | |||||
| ≥90% | 8 (25.0) | 85% | 0.714 | 86% | 0.670 |
| <90% | 24 (75.0) | 69% | 68% | ||
| BCL-2 | |||||
| Positive | 24 (75.0) | 74% | 0.455 | 72% | 0.629 |
| Negative | 8 (25.0) | 73% | 75% | ||
| BCL-6 | |||||
| Positive | 21 (65.6) | 89% | 0.072 | 90% | 0.107 |
| Negative | 11 (34.4) | 42% | 50% | ||
| C-MYC | |||||
| Positive | 25 (78.1) | 18% | 0.001* | 29% | 0.004* |
| Negative | 7 (21.9) | 48% | 48% | ||
| CD79 | |||||
| Positive | 7 (21.9) | 69% | 0.438 | 71% | 0.583 |
| Negative | 25 (78.1) | 73% | 70% | ||
| PAX-5 | |||||
| Positive | 10 (31.2) | 26% | 0.001* | 18% | 0.001* |
| Negative | 22 (68.8) | 94% | 95% | ||
| MUM1 | |||||
| Positive | 29 (90.6) | 73% | 0.617 | 73% | 0.547 |
| Negative | 3 (9.4) | 67% | 67% | ||
| CD5 | |||||
| Positive | 5 (15.6) | 100% | 0.279 | 100% | 0.228 |
| Negative | 27 (84.4) | 68% | 66% | ||
Values are presented as numbers and prescentages (%).
↵* Significant (p<0.05).